Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Inhibition of RAD51 (unknown origin) mediated homologous recombination
Assay data:1 Tested
SummaryPubMed CitationRelated BioAssays by Target
Inhibition of His-6 tagged human RAD51 mediated strand exchange at 1 to 2 uM relative to control
Inhibition of wild type human RAD51 expressed in Escherichia coli BL21-DE3 using 100 bp ssDNA probe as substrate assessed as prevention of D-loop formation preincubated for 5 mins followed by plasmid DNA addition and measured after 15 mins by agarose gel electrophoresis method
Assay data:1 Active, 1 Activity ≤ 1 µM, 3 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Inhibition of RAD51 (unknown origin) using 32P-labeled 90 mer ssDNA as substrate assessed as reduction in DNA D-loop formation preincubated for 30 mins followed by supercoiled pUC19 dsDNA addition and measured after 15 mins by agarose gel electrophoresis
Inhibition of RAD51 (unknown origin) using labeled 100-ss DNA as substrate assessed as reduction in DNA D-loop formation by [gamma-32P]ATP based scintillation counter method
Assay data:4 Active, 1 Activity ≤ 1 µM, 19 Tested
Inhibition of RAD51 (unknown origin) assessed as reduction in novel 58/33-dsDNA formation incubated for 1 hr by electrophoresis based DNA strand exchange assay
Assay data:5 Active, 1 Activity ≤ 1 µM, 10 Tested
Binding affinity to recombinant human His-tagged RAD51 expressed in Escherichia coli Rosetta2(DE3)pLysS cells in presence of BRC4 by 19F-NMR assay
Binding affinity to recombinant human His-tagged RAD51 expressed in Escherichia coli Rosetta2(DE3)pLysS cells by 19F-NMR assay
Assay data:1 Active, 1 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by Target
Inhibition of RAD51 in human U2OS cells at 20 to 80 uM measured by direct repeats green fluorescent protein (DR-GFP) reporter assay
Assay data:2 Active, 2 Tested
Binding affinity to RAD51 (158 to 180 residues) (unknown origin) assessed as random coil content at 15 uM by circular dichroism spectroscopy (Rvb = 39.2%)
Assay data:9 Tested
Binding affinity to RAD51 (158 to 180 residues) (unknown origin) assessed as beta-turn content at 15 uM by circular dichroism spectroscopy (Rvb = 16.2%)
Binding affinity to RAD51 (158 to 180 residues) (unknown origin) assessed as beta-sheet content at 15 uM by circular dichroism spectroscopy (Rvb = 17.7%)
Binding affinity to RAD51 (158 to 180 residues) (unknown origin) assessed as reduction in fluorescence intensity by fluorescence spectroscopy
Binding affinity to RAD51 (158 to 180 residues) (unknown origin) assessed as binding constant by fluorescence spectroscopy
Binding affinity to RAD51 (158 to 180 residues) (unknown origin) assessed as quenching rate constant by fluorescence spectroscopy
Binding affinity to RAD51 (158 to 180 residues) (unknown origin) assessed as alpha-helical content at 15 uM by circular dichroism spectroscopy (Rvb = 26.9%)
Stabilization of RAD51 foci in human cisplatin-resistant MCF7 cells assessed as increase in RAD51 positive cells at 20 uM pretreated with cisplatin for 8 hrs followed by compound addition and measured after 24 hrs by immunofluorescence microscopic analysis
Stabilization of RAD51 foci in human MCF7 cells assessed as increase in RAD51 positive cells at 20 uM pretreated with cisplatin for 8 hrs followed by compound addition and measured after 24 hrs by immunofluorescence microscopic analysis
Compound Primary Screening from US Patent US11291655: "RAD51 inhibitors"
Assay data:101 Active, 31 Activity ≤ 1 µM, 171 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
ELISA assay from Article 10.1021/acschembio.7b00707: "Synthetic Lethality Triggered by Combining Olaparib with BRCA2-Rad51 Disruptors."
Assay data:2 Tested
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on